Side-by-side · Research reference
AdipotidevsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Adipotide
Vilon
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Immune cell differentiation pathways, chromatin modification
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
Unknown — no HPA/HPG axis data
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
Vilon
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
Likely SQ or oral (Khavinson school uses both); no published ROA validation
Frequency
Not specified in available data
Unknown — literature does not specify chronic administration protocols
Evidence basis
Preclinical animal models only
Mouse / in vitro only
Human data
None — no clinical trials reported
—
Standard dose
—
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Duration
—
Not characterised in humans
Half-life
—
Not published — dipeptides typically <10 min plasma t½
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
Vilon
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
Vilon
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Adipotide
Vilon
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
06Stack Synergy
Adipotide
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation